Is there a role for positron emission tomography imaging in the early evaluation of prostate cancer relapse?

被引:0
作者
C Greco
G L Cascini
O Tamburrini
机构
[1] University of Magna Graecia,Division of Radiation Oncology
[2] University of Magna Graecia,Department of Radiology/Nuclear Medicine
来源
Prostate Cancer and Prostatic Diseases | 2008年 / 11卷
关键词
prostate cancer; biochemical relapse; PET/CT; F-FDG; C-acetate; C-choline;
D O I
暂无
中图分类号
学科分类号
摘要
The patient population with a rising prostate specific antigen (PSA) post-therapy with no evidence of disease on standard imaging studies currently represents the second largest group of prostate cancer patients. Little information is still available regarding the specificity and sensitivity of positron emission tomography (PET) tracers in the assessment of early biochemical recurrence. Ideally, PET imaging would allow one to accurately discriminate between local vs nodal vs distant relapse, thus enabling appropriate selection of patients for salvage local therapy. The vast majority of studies show a relatively poor yield of positive scans with PSA values <4 ng ml−1. So far, no tracer has been shown to be able to detect local recurrence within the clinically useful 1 ng ml−1 PSA threshold, clearly limiting the use of PET imaging in the post-surgical setting. Preliminary evidence, however, suggests that 11C-choline PET may be useful in selecting out patients with early biochemical relapse (PSA <2 ng ml−1) who have pelvic nodal oligometastasis potentially amenable to local treatment. The role of PET imaging in prostate cancer is gradually evolving but still remains within the experimental realm. Well-conducted studies comparing the merits of different tracers are needed.
引用
收藏
页码:121 / 128
页数:7
相关论文
共 291 条
  • [1] Scher HI(2000)Clinical states in prostate cancer: toward a dynamic model of disease progression Urology 55 323-327
  • [2] Heller G(2004)Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 22 537-556
  • [3] Scher HI(1999)Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1591-1597
  • [4] Eisenberger M(2002)International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy J Clin Oncol 20 3206-3212
  • [5] D'Amico AV(2000)Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 3352-3359
  • [6] Halabi S(2001)Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer Urology 58 393-399
  • [7] Small EJ(2003)Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer J Clin Oncol 21 4568-4571
  • [8] Morris M(2006)Management of the patient with a rising PSA alone Hematol Oncol Clin North Am 20 897-908
  • [9] Pound CR(2005)Rising prostate-specific antigen after primary prostate cancer therapy Nat Clin Pract Urol 2 174-182
  • [10] Partin AW(2002)Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era Cancer 95 281-286